Publications 2018

In 2018, the research group Clinical Effect Research published 48 articles in peer-reviewed journals. 56% of the articles were published in Level 2 journals (the 20% largest journals in their field). The average impact factor for the articles is 17.28 in 2018. The cumulative impact factor is 708.69.

1. Emilsson L, García-Albéniz X, Logan RW, Caniglia EC, Kalager M, Hernán MA. Examining Bias in Studies of Statin Treatment and Survival in Patients with Cancer. JAMA Oncol. 2018 Jan 1;4(1):63-70. doi: 10.1001/jamaoncol.2017.2752. PMID: 28822996.

Level 1

Impact factor: 20.87

2. Bugajski M, Kaminski MF. Devices for adenoma detection rate: Holy Grail or training tool? Gastrointest Endosc. 2018 Jan;87(1):241-242. doi: 10.1016/j.gie.2017.07.041. No abstract available. PMID: 29241852.

Level 1

Impact factor: 7.20

3. Emilsson L, Lebwohl B, Green PH, Murray JA, Mårild K, Ludvigsson JF. Mucosal healing and the risk of serious infections in patients with celiac disease. United European Gastroenterol J. 2018 Feb;6(1):55-62. doi: 10.1177/2050640617707868. Epub 2017 Apr 24. PMID: 29435314.

Level 1

Impact factor: 3.47

4. Juul FE. Lykkelig ensom. Tidsskr Nor Laegeforen. 2018 Feb 5;138(3). doi: 10.4045/tidsskr.17.1076. Print 2018 Feb 6. Norwegian. PMID: 29411572. 

5. Plate S, Emilsson L, Söderberg M, Brandberg Y, Wärnberg F. High experienced continuity in breast cancer care is associated with high health related quality of life. BMC Health Serv Res. 2018 Feb 20;18(1):127. doi: 10.1186/s12913-018-2925-0. PMID: 29458376.

Level 2

Impact factor: 1.84

6. Ludvigsson JF, Jarrick S, Murray JA, Emilsson L.Celiac Disease and Risk of Henoch-Schonlein Purpura: Population-based Cohort Study.J Clin Gastroenterol. 2018 Feb;52(2):141-145. doi: 10.1097/MCG.0000000000000750. PMID: 2 2.9687820222.

Level 1

Impact factor: 2.96

7. Kalager M. Helse uten kunnskap? Tidsskr Nor Laegeforen. 2018 Mar 5;138(5). doi: 10.4045/tidsskr.17.1058. Print 2018 Mar 6. Norwegian.

8. Emilsson L, Roy A, Lebwohl B, Green PHR, Ludvigsson JF. Depression and anxiety in caregivers of patients with celiac disease. Author's reply. Dig Liver Dis. 2018 Mar;50(3):320-321. doi: 10.1016/j.dld.2017.12.024. Epub 2018 Jan 3. PMID: 29366666.

Level 1

Impact factor: 3.28

9. Siemieniuk RAC, Harris IA, Agoritsas T, Poolman RW, Brignardello-Petersen R, Van de Velde S, Buchbinder R, Englund M, Lytvyn L, Quinlan C, Helsingen L, Knutsen G, Olsen NR, Macdonald H, Hailey L, Wilson HM, Lydiatt A, Kristiansen A. Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline. Br J Sports Med. 2018 Mar;52(5):313. doi: 10.1136/bjsports-2017-j1982rep. No abstract available. PMID: 29449218.

Level 2

Impact factor: 7.86

10. Roos E, Grotta A, Yang F, Bellocco R, Ye W, Adami HO, Wirdefeldt K, Trolle Lagerros Y.Body mass index, sitting time, and risk of Parkinson disease. Neurology. 2018 Apr 17;90(16):e1413-e1417. doi: 10.1212/WNL.0000000000005328. Epub 2018 Mar 21. PMID: 29661903.

Level 2

Impact factor: 8.05

11. Lauby-Secretan B, Vilahur N, Bianchini F, Guha N, Straif K; International Agency for Research on Cancer Handbook Working Group. Collaborators (23) Pinsky P, Blom J, Rabeneck L, Smith RA, Wiesner Ceballos C, Alhomoud S, Bretthauer M, Bulliard JL, Corley D, Forman D, Garcia Martinez M, Hoffmeister M, Hultcrantz R, Lansdorp-Vogelaar I, Nagtegaal I, Sangrajrang S, Sasieni P, Steele RJC, Sung JJY, Zauber AG, Augé Fradera JM, Robertson D, Senore C.The IARC Perspective on Colorectal Cancer Screening
N Engl J Med. 2018 May 3;378(18):1734-1740. doi: 10.1056/NEJMsr1714643. Epub 2018 Mar 26. No abstract available. PMID: 29580179.

Level 2

Impact factor: 79.26

12. Lousdal ML, Møller MH, Kristiansen IS, Kalager M, Wisløff T, Støvring H. The Screening Illustrator: separating the effects of lead-time and overdiagnosis in mammography screening. Eur J Public Health. 2018 May 22. doi: 10.1093/eurpub/cky085. PMID: 29796623.

Level 1 

Impact factor: 2.78

13. Trabert B, Poole EM, White E, Visvanathan K, Adami HO, Anderson GL, Brasky TM, Brinton LA, Fortner RT, Gaudet M, Hartge P, Hoffman-Bolton J, Jones M, Lacey JV Jr, Larsson SC, Mackenzie GG, Schouten LJ, Sandler DP, O'Brien K, Patel AV, Peters U, Prizment A, Robien K, Setiawan VW, Swerdlow A, van den Brandt PA, Weiderpass E, Wilkens LR, Wolk A, Wentzensen N, Tworoger SS; Ovarian Cancer Cohort Consortium (OC3). Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.J Natl Cancer Inst. 2018 May 31. doi: 10.1093/jnci/djy100. PMID: 29860330.

Level 2

Impact factor: 11.23

14. Juul FE, Garborg K, Bretthauer M, Skudal H, Øines MN, Wiig H, Rose Ø, Seip B, Lamont JT, Midtvedt T, Valeur J, Kalager M, Holme Ø, Helsingen L, Løberg M, Adami HO. Fecal Microbiota Transplantation for Primary Clostridium difficile Infection. N Engl J Med. 2018 Jun 28;378(26):2535-2536. doi: 10.1056/NEJMc1803103. Epub 2018 Jun 2. PMID: 29860912.

Level 2

Impact factor: 79.26

15. Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, Eide TJ, Skovlund E, Lekven J, Schneede J, Tveit KM, Vatn M, Ursin G, Hoff G; NORCCAP Study Group†. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Ann Intern Med. 2018 Jun 5;168(11):775-782. doi: 10.7326/M17-1441. Epub 2018 Apr 24. PMID: 29710125.

Level 2

Impact factor: 19.38

16. Emilsson L, García-Albéniz X, Hernan MA. Association of Statin Use With Overall and Cancer Survival-Reply. JAMA Oncol. 2018 Jul 1;4(7):1016-1017. doi: 10.1001/jamaoncol.2018.0736. PMID: 29800046.

Level 1

Impact factor:20,87

17. Pedersen IB, Løberg M, Hoff G, Kalager M, Bretthauer M, Holme Ø. Polypectomy techniques among gastroenterologists in Norway - a nationwide survey. Endosc Int Open. 2018 Jul;6(7):E812-E820. doi: 10.1055/a-0607-0727. Epub 2018 Jul 4. PMID: 29977999.

Level 1

Impact factor: NA

18. Bretthauer M, Kaminski MF, Emilsson L, Adami HO. Uppföljning efter polypektomi: riktlinjer, tro och evidens. Lakartidningen. 2017 Jul 6;114. pii: ERFF. Swedish. PMID:28696487

19. Halvorsen JA, Løberg M, Gjersvik P, Roscher I, Veierød MB, Robsahm TE, Nilsen LTN, Kalager M, Bretthauer M. Why a randomized melanoma screening trial is not a good idea. Br J Dermatol. 2018 Aug;179(2):532-533. doi: 10.1111/bjd.16784. Epub 2018 Jun 12. PMID: 29893490.

Level 2

Impact factor: 6.12

20. Juul, Frederik Emil. Blind nysgjerrighet. Tidsskr Nor Laegeforen. 2018 Aug 21;1165(12).  doi: 10.4045/tidsskr.18.0419. Print 2018 Aug 21. Norwegian.

21. Jodal HC, Løberg M, Holme Ø, Adami HO, Bretthauer M, Emilsson L, Ransohoff DF, Hoff G, Kalager M. Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients  -A Randomized Sigmoidoscopy Trial. Gastroenterology. 2018 Aug 27. pii: S0016-5085(18)34921-7. doi: 10.1053/j.gastro.2018.08.035. PMID: 30165051.

Level 2

Impact factor: 20.77

22. Løberg M, Kalager M, Hoff G.Tailoring the message with selective reporting. Eur J Epidemiol. 2018 Aug;33(8):773. doi: 10.1007/s10654-018-0416-6. Epub 2018 May 30. PMID: 29846866.

Level 2

Impact factor: 7.02

23. Wickberg Å, Magnuson A, Holmberg L, Adami HO, Liljegren G. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy. Breast. 2018 Aug 21;42:54-60. doi: 10.1016/j.breast.2018.08.097. PMID: 30176553.

Level 1

Impact factor: 2.95

24. Zhu D, Chung HF, Pandeya N, Dobson AJ, Kuh D, Crawford SL, Gold EB, Avis NE, Giles GG, Bruinsma F, Adami HO, Weiderpass E, Greenwood DC, Cade JE, Mitchell ES, Woods NF, Brunner EJ, Simonsen MK, Mishra GD. Body mass index and age at natural menopause: an international pooled analysis of 11 prospective studies. Eur J Epidemiol. 2018 Aug;33(8):699-710. doi: 10.1007/s10654-018-0367-y. Epub 2018 Feb 19. PMID: 29460096.

Level 2

Impact factor: 7.02

25. Bretthauer M, Kalager M. When no guideline recommendation is the best recommendation. Lancet. 2018 Sep 15;392(10151):898-899. doi: 10.1016/S0140-6736(18)31671-4. PMID: 30238877.

Level 2

Impact factor: 53.25

26. Bretthauer M, Kalager M, Weinberg DS. From Colorectal Cancer Screening Guidelines to Headlines: Beware! Ann Intern Med. 2018 Sep 18;169(6):405-406. doi: 10.7326/M18-1720. Epub 2018 Jul 10. PMID: 29987330.

Level 2

Impact factor: 19.38

27. Pandeya N, Huxley RR, Chung HF, Dobson AJ, Kuh D, Hardy R, Cade JE, Greenwood DC, Giles GG, Bruinsma F, Demakakos P, Simonsen MK, Adami HO, Weiderpass E, Mishra GD. Female reproductive history and risk of type 2 diabetes: A prospective analysis of 126 721 women. Diabetes Obes Metab. 2018 Sep;20(9):2103-2112. doi: 10.1111/dom.13336. Epub 2018 May 17.PMID: 29696756.

Level 1

Impact factor: 5.98

28. Bretthauer M, Goderstad JM, Løberg M, Emilsson L, Ye W, Adami HO, Kalager M.Uterine morcellation and survival in uterine sarcomas. Eur J Cancer. 2018 Sep;101:62-68. doi: 10.1016/j.ejca.2018.06.007. Epub 2018 Jul 17. PMID: 30025231.

Level 1 

Impact factor: 7.19

29. Kalager M, Wieszczy P, Lansdorp-Vogelaar I, Corley DA, Bretthauer M, Kaminski MF. Overdiagnosis in Colorectal Cancer Screening: Time to Acknowledge a Blind Spot. Gastroenterology. 2018 Sep;155(3):592-595. doi: 10.1053/j.gastro.2018.07.037. Epub 2018 Aug 1. PMID: 30076834.

Level 2

Impact factor: 20.77

30. Rutter MD, Beintaris I, Valori R, Chiu HM, Corley DA, Cuatrecasas M, Dekker E, Forsberg A, Gore-Booth J, Haug U, Kaminski MF, Matsuda T, Meijer GA, Morris E, Plumb AA, Rabeneck L, Robertson DJ, Schoen RE, Singh H, Tinmouth J, Young GP, Sanduleanu S. World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer. Gastroenterology. 2018 Sep;155(3):909-925.e3. doi: 10.1053/j.gastro.2018.05.038. Epub 2018 Jun 27.PMID: 29958856.

Level 2

Impact factor: 20.77

31. Holme Ø, Pedersen IB, Medhus AW, Aabakken L, Glomsaker T, Kvamme JM, Løberg M, Bretthauer M, Seip B, Kjellevold Ø, Jørgensen A, Furholm S, Hoff G, de Lange T. Endoscopy assistants influence the quality of colonoscopy. Endoscopy. 2018 Sep;50(9):871-877. doi: 10.1055/s-0044-101706. Epub 2018 Feb 14. PMID: 29444529.

Level 2 

Impact factor: 6.62

32. Pinsky PF, Loberg M, Senore C, Wooldrage K, Atkin W, Bretthauer M, Cross AJ, Hoff G, Holme O, Kalager M, Segnan N, Schoen RE. Number of Adenomas Removed and Colorectal Cancers Prevented in Randomized Trials of Flexible Sigmoidoscopy Screening. Gastroenterology. 2018 Oct;155(4):1059-1068.e2. doi: 10.1053/j.gastro.2018.06.040. Epub 2018 Jun 20.

Level 2

Impact factor:20.77

33. McMaster ML, Berndt SI, Zhang J, Slager SL, Li SA, Vajdic CM, Smedby KE, Yan H, Birmann BM, Brown EE, Smith A, Kleinstern G, Fansler MM, Mayr C, Zhu B, Chung CC, Park JH, Burdette L, Hicks BD, Hutchinson A, Teras LR, Adami HO, Bracci PM, McKay J, Monnereau A, Link BK, Vermeulen RCH, Ansell SM, Maria A, Diver WR, Melbye M, Ojesina AI, Kraft P, Boffetta P, Clavel J, Giovannucci E, Besson CM, Canzian F, Travis RC, Vineis P, Weiderpass E, Montalvan R, Wang Z, Yeager M, Becker N, Benavente Y, Brennan P, Foretova L, Maynadie M, Nieters A, de Sanjose S, Staines A, Conde L, Riby J, Glimelius B, Hjalgrim H, Pradhan N, Feldman AL, Novak AJ, Lawrence C, Bassig BA, Lan Q, Zheng T, North KE, Tinker LF, Cozen W, Severson RK, Hofmann JN, Zhang Y, Jackson RD, Morton LM, Purdue MP, Chatterjee N, Offit K, Cerhan JR, Chanock SJ, Rothman N, Vijai J, Goldin LR, Skibola CF, Caporaso NE.Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun. 2018 Oct 10;9(1):4182. doi: 10.1038/s41467-018-06541-2. PMID: 30305637.

Level 2

Impact factor: 12.35

34. Gaudet MM, Gierach GL, Carter BD, Luo J, Milne RL, Weiderpass E, Giles GG, Tamimi RM, Eliassen AH, Rosner B, Wolk A, Adami HO, Margolis KL, Gapstur SM, Garcia-Closas M, Brinton LA.Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype.Cancer Res. 2018 Oct 15;78(20):6011-6021. doi: 10.1158/0008-5472.CAN-18-0502. Epub 2018 Sep 5.PMID: 30185547.

Level 2

Impact factor: 9.13

35. Arroyo-Mühr LS, Lagheden C, Hultin E, Eklund C, Adami HO, Dillner J, Sundström K.Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study. Br J Cancer. 2018 Oct;119(9):1163-1168. doi: 10.1038/s41416-018-0311-7. Epub 2018 Oct 22. PMID: 30344308.

Level 2

Impact factor: 5.92

36. Bretthauer M. Screening for melanom er en dårlig idé. Tidsskr Nor Laegeforen. 2018 Oct 30;138(17). doi: 10.4045/tidsskr.18.0600. Print 2018 Oct 30. Norwegian. 

37. Bugajski M, Wieszczy P, Hoff G, Rupinski M, Regula J, Kaminski MF. Modifiable factors associated with patient-reported pain during and after screening colonoscopy. Gut. 2018 Nov;67(11):1958-1964. doi: 10.1136/gutjnl-2017-313905. Epub 2017 Sep 28.

Level 2

Impact factor: 17.01

38. Vleugels JLA, Hassan C, Senore C, Cassoni P, Baron JA, Rex DK, Ponugoti PL, Pellise M, Parejo S, Bessa X, Arnau-Collell C, Kaminski MF, Bugajski M, Wieszczy P, Kuipers EJ, Melson J, Ma K, Holman R, Dekker E, Pohl H. Performance measures for endoscopic retrograde cholangiopancreatography and endoscopic ultrasound: A European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Gastroenterology. 2018 Nov 2. pii: S0016-5085(18)35207-7. doi: 10.1053/j.gastro.2018.10.050. PMID:30395813.

Level 2

Impact factor: 20.77

39. Rawa-Golebiewska A, Kaminski MF. Colonoscopy quality: continuous improvement towards perfection. Endosc Int Open. 2018 Nov;6(11):E1310-E1311. doi: 10.1055/a-0732-5216. Epub 2018 Nov 7. PMID: 30411721.

Level 1

Impact factor: NA

40. Valori R, Cortas G, de Lange T, Balfaqih OS, de Pater M, Eisendrath P, Falt P, Koruk I, Ono A, Rustemović N, Schoon E, Veitch A, Senore C, Bellisario C, Minozzi S, Bennett C, Bretthauer M, Dinis-Ribeiro M, Domagk D, Hassan C, Kaminski MF, Rees CJ, Spada C, Bisschops R, Rutter M.  Performance measures for endoscopy services: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2018 Nov 13. doi: 10.1055/a-0755-7515.PMID: 30423593.

Level 2

Impact factor: 6.62

41. Domagk D, Oppong KW, Aabakken L, Czakó L, Gyökeres T, Manes G, Meier P, Poley JW, Ponchon T, Tringali A, Bellisario C, Minozzi S, Senore C, Bennett C, Bretthauer M, Hassan C, Kaminski MF, Dinis-Ribeiro M, Rees CJ, Spada C, Valori R, Bisschops R, Rutter MD. Performance measures for ERCP and endoscopic ultrasound: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2018 Nov;50(11):1116-1127. doi: 10.1055/a-0749-8767. Epub 2018 Oct 19.PMID: 30340220.

Level 2

Impact factor: 6.62

42. Zhu D, Chung HF, Pandeya N, Dobson AJ, Cade JE, Greenwood DC, Crawford SL, Avis NE, Gold EB, Mitchell ES, Woods NF, Anderson D, Brown DE, Sievert LL, Brunner EJ, Kuh D, Hardy R, Hayashi K, Lee JS, Mizunuma H, Giles GG, Bruinsma F, Tillin T, Simonsen MK, Adami HO, Weiderpass E, Canonico M, Ancelin ML, Demakakos P, Mishra GD. Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: A pooled analysis of individual data from 17 observational studies. PLoS Med. 2018 Nov 27;15(11):e1002704. doi: 10.1371/journal.pmed.1002704. eCollection 2018 Nov. PMID: 30481189.

Level 2

Impact factor: 11.67

43. Bugajski M, Kaminski MF. Sigmoidoscopy: a shortcut to effective screening or a dead end? Lancet Gastroenterol Hepatol. 2018 Nov 28. pii: S2468-1253(18)30410-2. doi: 10.1016/S2468-1253(18)30410-2. PMID: 30502932.

Level 1

Impact factor: 3.48 

44. Ludvigsson JF, Lebwohl B, Chen Q, Bröms G, Wolf RL, Green PHR, Emilsson L. Anxiety after coeliac disease diagnosis predicts mucosal healing: a population-based study. Aliment Pharmacol Ther. 2018 Nov;48(10):1091-1098. doi: 10.1111/apt.14991. Epub 2018 Oct 4. PMID: 30288774.

Level 1

Impact factor: 7.35

45. Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Andrén O, Steineck G, Adami HO, Johansson JE. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018 Dec 13;379(24):2319-2329. doi: 10.1056/NEJMoa1807801. PMID: 30575473.

Level 2

Impact factor: 79.26

46. Dekker E, Kaminski M. Take a pill for no more polyps: Is it that simple? Lancet. 2018 Dec 15;392(10164):2519-2521. doi: 10.1016/S0140-6736(18)32322-5. Epub 2018 Nov 19. PMID: 30466865.

Level 2

Impact factor: 53.25

47. Lagergren P, Schandl A, Aaronson NK, Adami HO, de Lorenzo F, Denis L, Faithfull S, Liu L, Meunier F, Ulrich C. Cancer survivorship: an integral part of Europe's research agenda. European Academy of Cancer Sciences. Mol Oncol. 2018 Dec 15. doi: 10.1002/1878-0261.12428. Review. PMID: 30552794.

Level 1

Impact factor: 5.26

48. Adami HO, Kalager M, Valdimarsdottir U, Bretthauer M, Ioannidis JPA. Time to abandon early detection cancer screening. Eur J Clin Invest. 2018 Dec 19:e13062. doi: 10.1111/eci.13062.PMID: 30565674.

Level 1

Impact factor: 3.08

Contributions in mass media and other publications

 

1. Dagens Medisin. Leder i Kreftregisteret hardt ut mot BMJ-studie. 2018 Jan 5. Norwegian.

2. Die Zeit, Germany. Schluss mit dem Mammografie-Screening. 2018 Jan 11. German.

3. Dagens Medisin. Mammografimarkering får kritikk.  2018 Mar 9. Norwegian.

4. Nordland Pluss. Grethe (49) fra Bodø er kvinne nummer en million. Samtidig raser debatten. 2018 Mar 9. Norwegian.

5. Avisa Nordland. Grethe ble kvinne nummer 1.000.000 – Mammografiprogrammet feiret en milepæl. 2018 Mar 10. Norwegian.

6. Aftenposten. En 5 minutters undersøkelse reduserer risikoen for å dø av tarmkreft. 2018 Apr 25. Norwegian.

7. Forskning.no. Anbefaler tarmkreftscreening for amerikanere fra 45 år. 2018 Jul 7. Norwegian.

8. Dagens Medisin. USA anbefaler å screene 45-åringer for tarmkreft. 2018 Jul 11. Norwegian.

9. Barua I, Holme Ø et al. Indremedisineren. Screening mot tarmkreft i hele Norge. 2018 Jul 12. Norwegian.

10. Dagens Medisin. Mener «retningslinje-lojalitet» bremser forskning. 2018 Sep 9. Norwegian.

11. Dagens Medisin. Det er ille når klinikere ikke vil delta i forskning fordi de ikke vil fravike retningslinjene. 2018 Sep 24. Norwegian.

12. Fysioterapeuten. – Vegrer seg for forskning på grunn av retningslinjer. 2018 Sep 27. Norwegian.

13. Kalager M., Kristiansen Sønbø I. Når kreft er ufarlig. 2018. Dagbladet. 2018 Nov 29. Norwegian.

14.Tidsskrift for Den norske legeforening. Screening for tarmkreft har effekt, men bare for menn. 2018 Oct 1.Norwegian.

15.Tidsskrift for Den norske legeforening. Legemiddelindustrien er ofte tungt involvert i studier.2018 Nov 30. Norwegian

16. Barua I. Kunstig intelligens kan i verste fall gjøre oss mindre intelligente. Morgenbladet. 2018 Dec 17. Norwegian.

Published Feb. 28, 2019 10:47 AM - Last modified Feb. 28, 2019 1:21 PM